Liteng Lin

1.5k citations

39 papers · 1.1k indexed · 1 hit paper · h-index 18

Impact in

Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis
Biomaterials top 5%
- Nanoparticle-Based Drug Delivery

Papers in ⓘ

Hepatology 18
- Hepatocellular Carcinoma Treatment and Prognosis 11
- Liver physiology and pathology 6
Immunology 13
- Immunotherapy and Immune Responses 6

Co-authors: Xintao Shuai (13 shared papers)Kangshun Zhu (28 shared papers)Mingyue Cai (25 shared papers)Jingjun Huang (19 shared papers)Wensou Huang (25 shared papers)Yong Wang (10 shared papers)Yongjian Guo (20 shared papers)Zecong Xiao (6 shared papers)
Journals: Biomedicine & Pharmacotherapy (3 papers)Biomaterials Science (3 papers)Journal of Controlled Release (2 papers)Nanomedicine Nanotechnology Biology and Medicine (2 papers)Biomedical Materials (1 paper)
Partner nations: China United States Hong Kong

In The Last Decade

Liteng Lin

38 papers receiving 1.1k citations

Hit Papers

align trajectories log scale

Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study 2022 · 117 citations

Peers

Countries citing papers authored by Liteng Lin

Since Specialization

Citations

This map shows the geographic impact of Liteng Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liteng Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liteng Lin more than expected).

Fields of papers citing papers by Liteng Lin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liteng Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liteng Lin. The network helps show where Liteng Lin may publish in the future.

Co-authors

The 25 scholars most cited alongside Liteng Lin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Liteng Lin Line = papers co-authored together Liteng Lin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 39 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-κB inhibitor for antitumor immunotherapy Science Advances ·Zecong Xiao, Zhenwei Su, Shisong Han, Jinsheng Huang, Liteng Lin, Xintao Shuai	2020	130
2	Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study Frontiers in Immunology ·Mingyue Cai, Wensou Huang, Jingjun Huang, Wenbo Shi, Yongjian Guo, Licong Liang, Jingwen Zhou, Liteng Lin, Bihui Cao, Ye Chen, Juan Zhou, Kangshun Zhu Hit paper breakdown →	2022	117
3	Aortic plaque-targeted andrographolide delivery with oxidation-sensitive micelle effectively treats atherosclerosis via simultaneous ROS capture and anti-inflammation Nanomedicine Nanotechnology Biology and Medicine ·Teng Wu, Xiaoyan Chen, Yong Wang, Hong Xiao, Yuan Peng, Liteng Lin, Wenhao Xia, Ming Long, Jun Tao, Xintao Shuai	2018	91
4	Nanodrug with ROS and pH Dual‐Sensitivity Ameliorates Liver Fibrosis via Multicellular Regulation Advanced Science ·Liteng Lin, Hongyang Gong, Rui Li, Jingjun Huang, Mingyue Cai, Tian Lan, Wensou Huang, Yongjian Guo, Zhimei Zhou, Yongcheng An, Zhiwei Chen, Licong Liang, Yong Wang, Xintao Shuai, Kangshun Zhu	2020	80
5	Co-Delivery of Doxorubicin and Anti-BCL-2 siRNA by pH-Responsive Polymeric Vector to Overcome Drug Resistance in In Vitro and In Vivo HepG2 Hepatoma Model Biomacromolecules ·Weitong Sun, Xiaoyan Chen, Chao Xie, Yong Wang, Liteng Lin, Kangshun Zhu, Xintao Shuai	2018	75
6	Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer International Journal of Biological Sciences ·Bihui Cao, Manting Liu, Jingjun Huang, Jingwen Zhou, Junping Li, Hui Lian, Wensou Huang, Yongjian Guo, Shuo Yang, Liteng Lin, Mingyue Cai, Cheng Zhi, Jingqiang Wu, Licong Liang, Yuling Hu, Hong‐Ming Hu, Jinping He, Baoxia Liang, Qi Zhao, Kangshun Zhu	2021	71
7	Nanodrug enhances post-ablation immunotherapy of hepatocellular carcinoma via promoting dendritic cell maturation and antigen presentation Bioactive Materials ·Zecong Xiao, Tan Li, Xinyao Zheng, Liteng Lin, Xiaobin Wang, Bo Li, Jingjun Huang, Yong Wang, Xintao Shuai, Kangshun Zhu	2022	51
8	Andrographolide Ameliorates Liver Fibrosis in Mice: Involvement of TLR4/NF‐κB and TGF‐β1/Smad2 Signaling Pathways Oxidative Medicine and Cellular Longevity ·Liteng Lin, Rui Li, Mingyue Cai, Jingjun Huang, Wensou Huang, Yongjian Guo, Liuhong Yang, Guizhi Yang, Tian Lan, Kangshun Zhu	2018	48
9	Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy Biomaterials Science ·Weitong Sun, Yong Wang, Mingyue Cai, Liteng Lin, Xiaoyan Chen, Zhong Cao, Kangshun Zhu, Xintao Shuai	2017	47
10	Sublethal heat stress-induced O-GlcNAcylation coordinates the Warburg effect to promote hepatocellular carcinoma recurrence and metastasis after thermal ablation Cancer Letters ·Ye Chen, Jiaxin Bei, Mingyu Liu, Jingjun Huang, Lulu Xie, Wensou Huang, Mingyue Cai, Yongjian Guo, Liteng Lin, Kangshun Zhu	2021	42
11	LncRNA DLEU2 aggravates the progression of hepatocellular carcinoma through binding to EZH2 Biomedicine & Pharmacotherapy ·Yongjian Guo, Mingjun Bai, Liteng Lin, Jingjun Huang, Yongcheng An, Licong Liang, Yaohong Liu, Wensou Huang	2019	42
12	A reduction and pH dual-sensitive nanodrug for targeted theranostics in hepatocellular carcinoma Biomaterials Science ·Mingyue Cai, Bo Li, Liteng Lin, Jingjun Huang, Yongcheng An, Wensou Huang, Zhimei Zhou, Yong Wang, Xintao Shuai, Kangshun Zhu	2020	31
13	Nanodrug removes physical barrier to promote T-cell infiltration for enhanced cancer immunotherapy Journal of Controlled Release ·Zecong Xiao, Yitong Tan, Yujun Cai, Jinsheng Huang, Xiaobin Wang, Bo Li, Liteng Lin, Yong Wang, Xintao Shuai, Kangshun Zhu	2023	30
14	MRI-visible and pH-sensitive micelles loaded with doxorubicin for hepatoma treatment Biomaterials Science ·Bo Li, Mingyue Cai, Liteng Lin, Weitong Sun, Zhimei Zhou, Shiyin Wang, Yong Wang, Kangshun Zhu, Xintao Shuai	2019	29
15	Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma Journal of Hepatocellular Carcinoma ·Jingjun Huang, Wensou Huang, Meixiao Zhan, Yongjian Guo, Licong Liang, Mingyue Cai, Liteng Lin, He Mingji, Hui Lian, Ligong Lu, Kangshun Zhu	2021	27
16	Amelioration of cirrhotic portal hypertension by targeted cyclooxygenase-1 siRNA delivery to liver sinusoidal endothelium with polyethylenimine grafted hyaluronic acid Nanomedicine Nanotechnology Biology and Medicine ·Liteng Lin, Mingyue Cai, Shaohui Deng, Wensou Huang, Jingjun Huang, Xinghua Huang, Mingsheng Huang, Yong Wang, Xintao Shuai, Kangshun Zhu	2017	24
17	Inhibition of CEMIP potentiates the effect of sorafenib on metastatic hepatocellular carcinoma by reducing the stiffness of lung metastases Cell Death and Disease ·Mingyu Liu, Lulu Xie, Yuying Zhang, Jianning Chen, Xiang Zhang, Ye Chen, Wensou Huang, Mingyue Cai, Licong Liang, Miaoling Lai, Jingjun Huang, Yongjian Guo, Liteng Lin, Kangshun Zhu	2023	18
18	Intratumoral Lactate Depletion Based on Injectable Nanoparticles−Hydrogel Composite System Synergizes with Immunotherapy against Postablative Hepatocellular Carcinoma Recurrence Advanced Healthcare Materials ·Ye Chen, Jiaxin Bei, Meijuan Chen, Weiguo Cai, Zhimei Zhou, Mingyue Cai, Wensou Huang, Liteng Lin, Yongjian Guo, Mingyu Liu, Xinkun Huang, Zecong Xiao, Zhili Xu, Kangshun Zhu	2023	17
19	T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma Journal for ImmunoTherapy of Cancer ·Xiaobin Wang, Qiaoyun Zhang, Jingwen Zhou, Zecong Xiao, Jianxin Liu, Shaohui Deng, Xiaoyang Hong, Wensou Huang, Mingyue Cai, Yongjian Guo, Jingjun Huang, Yong Wang, Liteng Lin, Kangshun Zhu	2023	17
20	Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-γ/NSDHL/SREBP1/TGF-β1 axis in hepatocellular carcinoma Biomedicine & Pharmacotherapy ·Lulu Xie, Mingyu Liu, Mingyue Cai, Wensou Huang, Yongjian Guo, Licong Liang, Weiguo Cai, Jianxin Liu, Wei Liang, Yitong Tan, Miaoling Lai, Liteng Lin, Kangshun Zhu	2023	15

About Liteng Lin

Liteng Lin is a scholar working on Hepatology, Immunology, Molecular Biology, Oncology and Biomedical Engineering, having authored 39 papers that have together received 1.1k indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (11 papers), Nanoplatforms for cancer theranostics (8 papers), Cancer Mechanisms and Therapy (7 papers), Liver physiology and pathology (6 papers), Liver Disease Diagnosis and Treatment (6 papers), Cancer Immunotherapy and Biomarkers (6 papers), Immunotherapy and Immune Responses (6 papers) and Nanoparticle-Based Drug Delivery (5 papers). The work is most often cited by research in Hepatology (280 citations), Biomaterials (206 citations), Immunology (266 citations), Cancer Research (163 citations) and Oncology (234 citations). Liteng Lin has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Xintao Shuai, Kangshun Zhu, Mingyue Cai, Jingjun Huang, Wensou Huang, Yong Wang, Yongjian Guo, Zecong Xiao, Licong Liang and Xiaoyan Chen. Their work appears in journals such as Biomedicine & Pharmacotherapy, Biomaterials Science, Journal of Controlled Release, Nanomedicine Nanotechnology Biology and Medicine and Biomedical Materials.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact